| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-12-08 | Pieris (Germany) Roche (Switzerland) | Anticalin®-based drug candidates against an undisclosed target | research - R&D - licensing | Cancer - Oncology | Research agreement | |
| 2015-12-07 | Addex Therapeutics (Switzerland) | opening of new premises |
Opening of new premises | |||
| 2015-12-07 | Immune Pharmaceuticals (USA - MA, Israel) | nomination |
Cancer - Oncology - Immunological diseases | Nomination | ||
| 2015-12-07 | Celgene (USA - NJ) AstraZeneca (UK) | durvalumab (MEDI4736) in combination with pomalidomide | hematological cancers including non-Hodgkin's lymphoma, myelodysplastic syndromes and multiple myeloma | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-12-07 | Aptuit (UK) | construction of new premises |
Technology - Services | Construction of new premises | ||
| 2015-12-07 | Voluntis (France) AstraZeneca (UK) | digital support service for women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trials of cediranib plus olaparib | ovarian cancer | collaboration |
Cancer - Oncology | Collaboration agreement |
| 2015-12-04 | Reneuron (UK) | nomination |
Regenerative Medicine | Nomination | ||
| 2015-12-04 | Amgen (USA - CA) Merck&Co (USA - NJ) | Blincyto® (blinatumomab), Keytruda® (pembrolizumab), AMG 820 | diffuse large B-cell lymphoma (DLBCL), advanced solid tumors | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-12-03 | Acacia Pharma (UK) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-12-03 | GE Global Research (USA - NY) Kite Pharma (USA - CA) | manufacturing system for engineered T cell therapy | collaboration |
Technology - Services | Collaboration agreement | |
| 2015-12-03 | Baxalta (USA - IL) | Global Innovation Center | opening of new premises |
Rare diseases - Genetic diseases - Hematological diseases - Immunological diseases - Cancer- Oncology | Opening of new premises | |
| 2015-12-03 | Txcell (France) Masthercell (Belgium) | ASTrIA platform | production manufacturing |
Autoimmune diseases – Inflammatory diseases - Digestive diseases - Technology - Services | Production agreement | |
| 2015-12-03 | Bluebird bio (USA - MA) ViroMed (South Korea) | chimeric antigen receptor (CAR) T cell therapies | solid tumors | Cancer - Oncology | Establishment of a new subsidiary in the EU | |
| 2015-12-03 | Zealand Pharma (Denmark) | nomination |
Nomination | |||
| 2015-12-03 | BiolineRx (Israel) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-12-02 | Affimed (Germany) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-12-02 | Integragen (France) University Hospital Grosshadern (GErmany) | hsa-miR-31-3p biomarker | metastatic colorectal cancer (mCRC) | collaboration clinical research |
Cancer - Oncology | Collaboration agreement |
| 2015-12-02 | Auspherix (Australia) Auspherix Limited (UK) | nomination |
Infectious diseases | Nomination | ||
| 2015-12-02 | Y-mAbs Therapeutics (USA - NY) Patheon Biologics (USA - NC) | production manufacturing |
Cancer - Oncology | Production agreement | ||
| 2015-12-01 | Roche (Switzerland) Upsher-Smith Laboratories (USA - MN) | Vascular Adhesion Protein 1 (VAP-1) inhibitor | licensing |
Licensing agreement |
